Precigen (PGEN) Fireside chat summary

Introduction and agenda

• Discussion focused on the commercial launch and clinical impact of PAPZIMEOS, the first immunotherapy for adult RRP, following its FDA approval in 2025 and the company's transition to commercial stage in 2026.

Background and experience of the speaker

• Dr. Helen Sabzevari highlighted her experience in developing innovative therapies and the unique aspects of the AdenoVerse platform, emphasizing full IP ownership and differentiation from other adenoviral vectors.

Current industry trends

• Growing recognition of RRP as a significant unmet need, with increased disease awareness and underdiagnosis being addressed through advocacy and data analysis.

• Shift toward immunotherapies and platform technologies that enable rapid development and regulatory efficiencies.